Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study

The obtained results confirm the high efficacy and safety of Revelise in patients with IS. The wide practical use in various patient groups is justified by an up-to-date patient selection algorithm. This includes patients aged 80 years and older with minor stroke (NIHSS score< 5) who receive treatment with antiplatelet agents or anticoagulants, as well as staged reperfusion. The obtained results are consistent with those of previously published studies with a similar design.